News - Mergers & Acquisitions, Anti-virals


Popular Filters

Ventrus Biosciences boosted on merger plan with Assembly Pharma


USA-based Ventrus Biosciences saw its shares leap 9.4% to $1.16 in pre-market trading, as it announced…

Anti-viralsAssembly BiosciencesAssembly PharmaceuticalsBiotechnologyMergers & AcquisitionsVentrus Biosciences

Biozone Pharma plans reverse merger with Cocrystal Discovery


USA-based Biozone Pharmaceuticals shares dropped nearly 5.5% when it revealed last week it had agreed…

Anti-viralsBiotechnologyBiozone PharmaceuticalsCocrystal DiscoveryMergers & Acquisitions

Vivaldi Biosciences acquires clinical stage influenza vaccine assets


Privately-held US biotech firm Vivaldi Biosciences has acquired from Baxter Healthcare R&D assets, including…

Anti-viralsBaxter HealthcareBaxter InternationalBiotechnologyMergers & AcquisitionsVaccinesVivaldi Biosciences

FDA approves Protein Sciences egg-free flu vaccine Flublok; and Octapharma's Octaplas


The US Food and Drug Administration revealed it has approved privately-held US biotech firm Protein Sciences…

Anti-viralsBiotechnologyFlublokMergers & AcquisitionsNorth AmericaOctapharmaOctaplasPanblokPharmaceuticalProtein Sciences CorpRegulationVaccines

Revised terms for ViiV Healthcare and Shionogi HIV partnership


UK pharma giant GlaxoSmithKline (LSE: GSK) says that Healthcare, its HIV/AIDS joint venture with Pfizer,…

Anti-viralsdolutegravirGlaxoSmithKlineMergers & AcquisitionsPfizerPharmaceuticalShionogiViiV Healthcare

BioCryst and Presidio to merge, creating new competitor in HCV arena


USA drugmaker BioCryst Pharmaceuticals (Nasdaq: BCRX) has signed a definitive accord to acquire privately…

Anti-viralsBioCryst PharmaceuticalsMergers & AcquisitionsPharmaceuticalPresidio Pharmaceuticals

Australia's Benitec to acquire US RNAi firm Tacere


Australia-based Benitec Biopharma (ASX: BLT) said last Friday that it has executed an agreement to acquire…

Anti-viralsBenitec BiopharmaBiotechnologyMergers & AcquisitionsPharmaceuticalTacere Therapeutics

Achillion Pharma moves up as a contender in the HCV market, GlobalData believes


On September 27, Achillion Pharmaceuticals (Nasdaq: ACHN) released news of positive results surrounding…

ACH-3102Achillion PharmaceuticalsAnti-viralsBiotechnologyMergers & AcquisitionsPharmaceuticalResearch

Synergy Pharma gains rights to shingles drug from Bristol-Myers


US biopharma firm Synergy Pharmaceuticals (Nasdaq: SGYP) has signed an asset purchase agreement with…

Anti-viralsBiotechnologyBristol-Myers SquibbFV-100Mergers & AcquisitionsSynergy Pharmaceuticals

Merck & Co out to lead in hepatitis C


US drugs giant Merck & Co (NYSE: MRK) aims to become a leader in the hepatitis C space, the company’s…

Anti-viralsMerck & CoMergers & AcquisitionsPharmaceuticalResearch

RusNano to start production of vaccines and organogels


Russia’s RusNano (Russian Corporation of Nanotechnologies) has signed an agreement with Russian…

Anti-viralsBiotechnologyCardio-vascularEpidbiomedEuropeFinancialMarkets & MarketingMergers & AcquisitionsNanolekOncologyRusNanoVaccines

Bristol-Myers to buy hep C drug developer for $2.5 billion


Looking to bolster its drug pipeline in the face of US patent expiry of one of its best selling drugs,…

Anti-viralsBristol-Myers SquibbInhibitexMergers & AcquisitionsPharmaceutical

Gilead expands hepatitis C R&D portfolio with $11 billion buy of Pharmasset


In its biggest M&D deal to date, Gilead Sciences (Nasdaq: GILD) says it has signed a definitive agreement…

Anti-viralsBiotechnologyGilead SciencesMergers & AcquisitionsmericitabinePharmaceuticalPharmasset

Immdal sells Newport to Ewopharma; establishes Immcell


Privately-held Irish drugmaker Immdal last week announced the sale of its subsidiary Newport Pharmaceuticals…

Anti-viralsEwopharmaImmdalMergers & AcquisitionsNewport PharmaPharmaceutical

Roche to boost hep C offerings with $230 million acquisition of Anadys Pharma


In a further move to broaden in presence outside its current domination in the oncology sector, Swiss…

Anadys PharmaceuticalsAnti-viralsMergers & AcquisitionsPharmaceuticalRoche

Teva invests $7.5 million in Cocrystal Discovery for novel hepatitis C antiviral


In a further move to boost its non-generics activities, Israel’s Teva Pharmaceutical Industries…

Anti-viralsCocrystal DiscoveryLicensingMergers & AcquisitionsPharmaceuticalRegulationTeva Pharmaceutical Industries

Gilead gains US approval for Complera, resolves manufacturing problem and buys Genentech facility


In what were a couple of busy news days for US biotech firm Gilead Sciences (Nasdaq: GILD), the company…

Anti-viralsBiotechnologyCompleraGenentechGilead SciencesJohnson & JohnsonMergers & AcquisitionsNorth AmericaPharmaceuticalRegulationRocheTibotec

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top